Macitentan

Top 2024 PAH articles highlighted FDA approvals for macitentan-tadalafil combo and sotatercept, salt substitutes reducing hypertension in older adults, and similar PAH treatment outcomes regardless of diagnosis time. Kidney transplant management for PH patients was also emphasized.

Merck's Winrevair, added to background therapy, helped severe lung hypertension patients stay alive and avoid invasive care longer. The ZENITH trial's interim data showed Winrevair outperformed placebo, potentially expanding its use and peak annual earnings to $5 billion. Winrevair treats pulmonary arterial hypertension, improving walking speed and delaying complications, with the ZENITH study focusing on severe cases.

Johnson & Johnson reported strong Q3 2024 results with 6.3% operational sales growth, driven by high-innovation and high-growth markets. Key achievements include FDA approvals for Rybrevant and Tremfya, significant sales from Darzalex and Carvykti, and strategic acquisitions like Shockwave and V-Wave. Despite challenges in Asia-Pacific, the company remains confident in its growth trajectory and has increased its 2024 financial guidance.

The European Commission approves Johnson and Johnson's Yuvanci, a single-pill combination therapy for pulmonary arterial hypertension, based on Phase III A DUE study results showing significant improvements in pulmonary vascular resistance and pulmonary haemodynamic improvement.